{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1"},{"groupId":"OG001","value":"36.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"495"},{"groupId":"OG001","value":"496"}],"units":"Participants"}],"description":"The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.","groups":[{"description":"Participants received trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.","id":"OG000","title":"Trastuzumab Emtansine"},{"description":"Participants received lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 mg/m\\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Participants of this group were allowed to cross over to receive trastuzumab emtansine based on statistically significant OS benefit in favor of trastuzumab emtansine demonstrated in second interim analysis.","id":"OG001","title":"Lapatinib + Capecitabine"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants on the basis of the treatment assigned at randomization.","reportingStatus":"POSTED","timeFrame":"From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)","title":"Percentage of Participants Who Died: Second Interim Analysis","type":"PRIMARY","unitOfMeasure":"percentage of participants"}